NCT06749886 2024-12-27
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting